[EN] BENZOTHIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION<br/>[FR] INHIBITEURS BENZOLTHIAZOLYLÉS DE L'ACTIVATION DE PRO-MÉTALLOPROTÉINASE DE MATRICE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2012162463A1
公开(公告)日:2012-11-29
This invention relates to benzothiazole (formula I) and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
To address drug resistance caused by ALK kinase mutations, especially the most refractory and predominant mutation G1202R for the second-generation ALK inhibitor, a series of new diary-laminopyrimidine analogues were designed by incorporating a resorcinol moiety (A-ring) to interact the ALK kinase domain where the G1202R is located. Compound 12d turns out as the most potent with IC50 values of 1.7, 3.5, and 1.8 nM against ALK wild type, gatekeeper mutant L1196M, and the G1202R mutant, respectively. More importantly, compound 12d has excellent inhibitory effects against the proliferation of BaF3 cells specifically expressing ALK wild type, gatekeeper L1196M, and the most challenging mutant G1202R, with IC50 values all less than 1.5 nM. Collectively, compound 12d is worthy of further investigation as a new more potent third-generation ALK inhibitor to circumvent drug resistance of both the first-generation and the second-generation inhibitors. (C) 2017 Published by Elsevier Masson SAS.
Verkade; van Dijk; Meerburg, Recueil des Travaux Chimiques des Pays-Bas, 1946, vol. 65, p. 346,350, 357
作者:Verkade、van Dijk、Meerburg
DOI:——
日期:——
Blanksma; van der Weyden, Recueil des Travaux Chimiques des Pays-Bas, 1940, vol. 59, p. 629,631